Aktis Oncology reports Q2 2026 results, three Phase 1b trials now underway or cleared

Aktis Oncology reported second quarter 2026 results on August 13, 2026, detailing progress across its two clinical-stage radioconjugate programs, AKY-1189 and AKY-2519.

The company presented first-in-human clinical imaging and dosimetry data for AKY-2519 spanning several B7-H3 expressing tumor types, including metastatic castration-resistant prostate cancer, at the ASCO Annual Meeting in May 2026¹. Aktis said the data showed strong tumor uptake and retention with minimal exposure to healthy tissue, which the company said points to a wide therapeutic window and a profile distinct from currently approved radiopharmaceuticals. The imaging and dosimetry procedures were generally well tolerated, with no adverse events or infusion-related reactions reported.¹

On the trial front, Aktis is enrolling patients in the Phase 1b BActinium-1 trial of AKY-2519 in PLUVICTO-naive and PLUVICTO-experienced metastatic castration-resistant prostate cancer patients¹, and has received regulatory clearance to start a separate Phase 1b trial, BActinium-2, testing AKY-2519 across other tumor types expressing B7-H3¹. For AKY-1189, the company continued enrolling patients in the Phase 1b NECTINIUM-2 trial covering urothelial cancer, breast cancer, and other Nectin-4 expressing solid tumors¹.

Looking ahead, Aktis expects to begin the BActinium-2 basket trial in lung and other B7-H3 expressing tumors in the second half of 2026, with preliminary mCRPC data expected in 2027¹, while preliminary NECTINIUM-2 data is expected in the first quarter of 2027¹.

Financially, the company held $517.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, up from $226.8 million at year-end 2025, an amount it said should fund operations into 2029.¹